Pipeline Moves: Advancement prospects plunge for Parkinson’s ...

October 2, 2023

Phase III trial for Parkinson's disease terminated, reducing DNL-151's LoA to 14%. LIB Therapeutics' lerodalcibep shows promise in HeFH, increasing LoA to 65%. AstraZeneca's MEDI-7352 completes Phase IIb for osteoarthritis pain, PTSR rises to 45%. Incyte's itacitinib completes Phase II for CRS, PTSR increases to 60%.

Related Clinical Trials

Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction

A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

A Study of the Efficacy and Safety of MEDI7352 in Subjects With Painful Osteoarthritis of the Knee

A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale

Reference News

clinicaltrialsarena.com

Pipeline Moves: Advancement prospects plunge for Parkinson’s ...